Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics
Abstract
Aim: Biologics and apremilast have advanced psoriasis management by adding treatment options. This study evaluated persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics. Methods: Administrative claims data for adults starting apremilast or biologics from 1 January 2013 to 30 June 2016 were matched based on demographics. Results: Apremilast (n = 703) and biologics (n = 1378) had similar baseline characteristics. 12-month persistence and adherence rates were similar. Adjusted total healthcare costs were lower with apremilast versus biologics (p < 0.001) due to lower total outpatient pharmacy costs (p < 0.001). Conclusion: Real-world apremilast users had similar adherence and lower total healthcare costs versus biologic users. Apremilast's cost advantage was evident regardless of whether the patients were persistent or nonpersistent, or switched or did not switch treatments.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest
1.
Feldman SR, Goffe B, Rice G et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am. Health Drug Benefits 9(9), 504–513 (2016).
• Describes how psoriasis is a complex, costly disease and how patients and healthcare providers manage the various psoriasis treatment options so patients can obtain optimal care.
2.
National Institute of Arthritis and Musculoskeletal and Skin Disease. Questions and answers about psoriasis (2017). www.niams.nih.gov/health-topics/psoriasis.
3.
World Health Organization. Global report on psoriasis (2016). http://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf;jsessionid=FA9000ED205E06CBB51120CECA4F1E6E?sequence=1.
4.
Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980–1983. Arch. Dermatol. 127(8), 1184–1187 (1991).
5.
Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 23(Suppl. 2), 1–70 (2009).
6.
Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol. 92(5), 668–674 (2017).
7.
Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 151(6), 651–658 (2015).
8.
National Psoriasis Foundation. About psoriasis and psoriatic arthritis in children (2018). www.psoriasis.org/parents/about-psoriasis.
9.
National Psoriasis Foundation. Topical treatments (2018). www.psoriasis.org/about-psoriasis/treatments/topicals.
10.
National Psoriasis Foundation. Traditional systemic medications (2018). www.psoriasis.org/about-psoriasis/treatments/systemics.
11.
Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. PT 40(8), 495–500 (2015).
12.
Guerriero F, Orlando V, Monetti VM, Russo V, Menditto E. Biological therapy utilization, switching, and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy. Clinicoecon. Outcomes Res. 9, 741–748 (2017).
13.
Gisondi P, Del Giglio M, Girolomoni G. Treatment approaches to moderate to severe psoriasis. Int. J. Mol. Sci. 18(11), E2427 (2017).
14.
National Psoriasis Foundation. Moderate to severe psoriasis and psoriatic arthritis: biologic drugs (2018). www.psoriasis.org/about-psoriasis/treatments/biologics.
15.
Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des. Devel. Ther. 7, 201–210 (2013).
• Models the cost per responder for psoriasis patients receiving etanercept or ustekinumab treatment, and the article provides an older estimate of the costs of psoriasis patients treated with select biologics.
16.
Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J. Dermatolog. Treat. 22(3), 138–143 (2011).
• Reports the average wholesale cost of biologics over time, which serves as an estimate of the price of biologics for patients with psoriasis.
17.
Cheng J, Feldman SR. The cost of biologics for psoriasis is increasing. Drugs Context 3, 212266 (2014).
18.
Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther. Adv. Musculoskelet. Dis. 9(2), 45–53 (2017).
19.
Goldenberg G, Lanoue J, Dong J. New oral therapies for psoriasis: a comprehensive review. J. Clin. Aesthet. Dermatol. 9(8), 25–28 (2016).
20.
Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L. Intentional and unintentional medication non-adherence in psoriasis: the role of patients’ medication beliefs and habit strength. J. Invest. Dermatol. 138(4), 785–794 (2018).
21.
Singh SM, Narang T, Vinay K et al. Clinic-based group multi-professional education causes significant decline in psoriasis severity: a randomized open label pilot study. Indian Dermatol. Online J. 8(6), 454–459 (2017).
Information & Authors
Information
Published In
Copyright
© 2018 Future Medicine Ltd.
History
Received: 19 September 2018
Accepted: 19 October 2018
Published online: 2 November 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0097
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Andreas Pinter, Marcus Schulte, Nils Kossack, Marc Pignot, Michael Schultze, Andrea Feldhus, Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database, Journal of Medical Economics, 10.1080/13696998.2025.2452054, 28, 1, (207-220), (2025).
- Celine Miyazaki, Junya Masuda, Phiona I-Ching Tsai, Hidehisa Saeki, Factors Affecting Treatment Persistence in Japanese Patients with Psoriasis Prescribed Biologics: A Real-World Study Using an Insurance Claim Database, Dermatology and Therapy, 10.1007/s13555-024-01274-1, 14, 11, (2999-3015), (2024).
- Dominic Pilon, Timothy Fitzgerald, Maryia Zhdanava, Amanda Teeple, Laura Morrison, Aditi Shah, Patrick Lefebvre, Risk of Treatment Discontinuation among Patients with Psoriasis Initiated on Ustekinumab and Other Biologics in the USA, Dermatology and Therapy, 10.1007/s13555-022-00707-z, 12, 4, (971-987), (2022).
- Masayuki Tanaka, Yasushi Ozeki, Fujio Matsuyama, Tatsunori Murata, Shinichi Imafuku, Taichi Nakamura, Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis, Dermatology and Therapy, 10.1007/s13555-021-00659-w, 12, 2, (451-466), (2021).
- Andrea Picchianti-Diamanti, Francesca Romana Spinelli, Maria Manuela Rosado, Fabrizio Conti, Bruno Laganà, Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases, International Journal of Molecular Sciences, 10.3390/ijms22052638, 22, 5, (2638), (2021).
- Shammy Jindal, Rajendra Awasthi, Dhananjay Singhare, Giriraj T. Kulkarni, Topical delivery of Tacrolimus using liposome containing gel: An emerging and synergistic approach in management of psoriasis, Medical Hypotheses, 10.1016/j.mehy.2020.109838, 142, (109838), (2020).
- Jashin J Wu, Corey Pelletier, Brian Ung, Marc Tian, Ibrahim Khilfeh, Jeffrey R Curtis, Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics, Journal of Comparative Effectiveness Research, 10.2217/cer-2020-0045, 9, 11, (767-779), (2020).
- David L Kaplan, Brian L Ung, Corey Pelletier, Chuka Udeze, Ibrahim Khilfeh, Marc Tian,
Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
, ClinicoEconomics and Outcomes Research, 10.2147/CEOR.S251775, Volume 12, (369-377), (2020). - Yves Poulin, Catherine Beauchemin, Catherine Royer, Anne-Julie Gaudreau, Clarabella Yim, Fei Fei Liu, Jean Lachaine, Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization, Journal of Cutaneous Medicine and Surgery, 10.1177/1203475420936652, 24, 6, (573-587), (2020).
- Eran Shavit, Neil H. Shear, An update on the safety of apremilast for the treatment of plaque psoriasis, Expert Opinion on Drug Safety, 10.1080/14740338.2020.1744562, 19, 4, (403-408), (2020).